TY - JOUR
T1 - Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo
T2 - Eastern cooperative oncology group trial E2196
AU - Zucker, Stanley
AU - Wang, Molin
AU - Sparano, Joseph A.
AU - Gradishar, William J.
AU - Ingle, James N.
AU - Davidson, Nancy E.
N1 - Funding Information:
The authors acknowledge Stella Ranuncolo, MD, for her review of the article. This study was conducted by the ECOG (Robert L. Comis, MD, Chair) and was supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA14958, CA17145, CA13650, and CA16116 and from the National Cancer Institute, National Institutes of Health, and Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
PY - 2006/2
Y1 - 2006/2
N2 - Background: The purpose of this study was to evaluate the prognostic and predictive utility of measuring plasma levels of matrix metalloproteinase (MMP)-7 and MMP-9 in patients with metastatic breast cancer (MBC) treated with the oral MMP inhibitor (MMPI) marimastat or a placebo. Patients and Methods: We measured plasma levels of MMP-7 and M MP-9 using an enzyme-linked immunoassay method in 140 evaluable patients with MBC enrolled on a multicenter clinical trial that compared the MMPI marimastat with placebo. Specimens were collected after completion of first-line chemotherapy in patients who had responding or stable disease and 3, 6, and 12 months after initiation of marimastat (10 mg orally twice daily) or placebo. Results: Baseline plasma MMP-7 and MMP-9 level s did not correlate with each other or with progression-free or overall survival. In addition, serial evaluation of plasma MMP-7 and MMP-9 levels revealed no significant changes over time in the marimastat or placebo groups or any correlation with trough plasma marimastat level. Conclusion: We conclude that measurement of plasma MMP-7 or MMP-9 levels, as performed in our trial, was not a useful prognostic or predictive factor in patients with MBC or in patients treated with an MMPI.
AB - Background: The purpose of this study was to evaluate the prognostic and predictive utility of measuring plasma levels of matrix metalloproteinase (MMP)-7 and MMP-9 in patients with metastatic breast cancer (MBC) treated with the oral MMP inhibitor (MMPI) marimastat or a placebo. Patients and Methods: We measured plasma levels of MMP-7 and M MP-9 using an enzyme-linked immunoassay method in 140 evaluable patients with MBC enrolled on a multicenter clinical trial that compared the MMPI marimastat with placebo. Specimens were collected after completion of first-line chemotherapy in patients who had responding or stable disease and 3, 6, and 12 months after initiation of marimastat (10 mg orally twice daily) or placebo. Results: Baseline plasma MMP-7 and MMP-9 level s did not correlate with each other or with progression-free or overall survival. In addition, serial evaluation of plasma MMP-7 and MMP-9 levels revealed no significant changes over time in the marimastat or placebo groups or any correlation with trough plasma marimastat level. Conclusion: We conclude that measurement of plasma MMP-7 or MMP-9 levels, as performed in our trial, was not a useful prognostic or predictive factor in patients with MBC or in patients treated with an MMPI.
KW - Matrix metalloproteinase inhibitors
KW - Phase III trials
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=33645642050&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645642050&partnerID=8YFLogxK
U2 - 10.3816/CBC.2006.n.006
DO - 10.3816/CBC.2006.n.006
M3 - Article
C2 - 16595036
AN - SCOPUS:33645642050
SN - 1526-8209
VL - 6
SP - 525
EP - 529
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
IS - 6
ER -